Jennifer E. Hardingham

Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

Timothy Price, Jennifer E. Hardingham, Chee Khoon Lee et al. · Journal of Clinical Oncology · 2011 · 209 citations · Full text

Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease

Jennifer E. Hardingham, Peter J. Hewett, Robert Sage et al. · International Journal of Cancer · 2000 · 145 citations

Surgical Oncology, Colorectal Surgery, Gastroenterology +18

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Jennifer Mooi, Pratyaksha Wirapati, Rebecca Asher et al. · Annals of Oncology · 2018 · 136 citations · Full text

Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction.

Jennifer E. Hardingham, Dusan Kotasek, Belinda J. Farmer et al. · PubMed · 1993 · 121 citations

Engineering, Immunology, Pathology +18

Detection of Circulating Tumor Cells in Colorectal Cancer by Immunobead-PCR Is a Sensitive Prognostic Marker for Relapse of Disease

Jennifer E. Hardingham, Dusan Kotasek, Robert Sage et al. · Molecular Medicine · 1995 · 116 citations · Full text

Sensitive Prognostic Marker, Tumor Biology, Prognostic Biomarkers +10